Skip to main content
GutCited

Berberine 用于 Small Intestinal Bacterial Overgrowth (SIBO)

C

Herbal antimicrobial protocol including berberine showed comparable efficacy to rifaximin for SIBO in retrospective study. Prospective RCT data limited.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Dberberine\u0026condition\u003Dsibo'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    


    
    

      Widget powered by
      .
      Free, no account required.
    

  




    








    

        

            C

        

        

            
结论

            
            
Herbal antimicrobial protocol including berberine showed comparable efficacy to rifaximin for SIBO in retrospective study. Prospective RCT data limited.

            
            
        

    










    

  
Key Study Findings





    

        
        

            

                
                    Meta-Analysis
                
                
                n=1552
                
                
                
            

            
                Comparative efficacy of diverse therapeutic regimens for small intestinal bacterial overgrowth: a systematic network meta-analysis.
            
            

                
                Dose: None
                
                
                vs: Multiple comparators (network meta-analysis)
                
                
                Outcome: SIBO eradication rate
                
                
                效果: Berberine highest SUCRA
                
                
                None
                
            

            
            
研究人群: Adults with SIBO from 30 RCTs

            
        

        
        

            

                
                    Randomized Controlled Trial
                
                
                
                2 weeks
                
                
                Open-label
                
            

            
                Berberine and rifaximin effects on small intestinal bacterial overgrowth: Study protocol for an investigator-initiated, double-arm, …
            
            

                
                Dose: 400 mg d
                
                
                vs: control
                
                
                Outcome: a negative breath test
                
                
                效果: None
                
                
                None
                
            

            
            
研究人群: Long-term abdominal discomfort and avoiding excessive examination

            
        

        
    







    
    

        
        

            

  
Key Statistics





            


    

        
2

        
研究数量

    

    

        
180

        
受试者

    

    

        
            
            ↑
            
        
        
Positive

    

    

        C

        
等级

    




        


        
        
        

            

  
Referenced Papers





            

                
                

                    

                        
                            Comparative efficacy of diverse therapeutic regimens for small intestinal bacterial overgrowth: a systematic network meta-analysis.
                        
                        
                            
                                Other
                            
                            
                            
                        
                    

                    

                        Therapeutic advances in …
                        2025
                        
                    

                

                
                

                    

                        
                            Berberine and rifaximin effects on small intestinal bacterial overgrowth: Study protocol for an investigator-initiated, double-arm, open-label, randomized clinical trial (BRIEF-SIBO …
                        
                        
                            
                                Other
                            
                            
                            
                        
                    

                    

                        Frontiers in pharmacology
                        2023
                        
                        8 次引用
                        
                    

                

                
            

        

        

        
        
        

            

  
Dosage & Usage





            
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units


            
            

                
常用剂量

                

                    
                    

                        
general:

                        
500-1,500 mg/day in divided doses

                    

                    
                    

                        
siboprotocol:

                        
500 mg two to three times daily for 4 weeks (as part of herbal antimicrobial protocol)

                    

                    
                    

                        
giantimicrobial:

                        
500 mg twice daily

                    

                    
                

                
                

                    上限： Generally well-tolerated up to 1,500 mg/day in divided doses
                

                
            

            

            
            

                
研究中使用的剂量

                

                    

                        
                            

                                剂量
                                持续时间
                                效果
                                N
                            

                        
                        
                            
                            

                                None
                                --
                                
                                    
                                    Positive
                                    
                                
                                1552
                            

                            
                            

                                400 mg d
                                2 weeks
                                
                                    
                                    Mixed
                                    
                                
                                --
                            

                            
                        
                    

                

            

            

            
            

                最佳服用时间： With meals; divide doses throughout the day (do not take full daily dose at once)
            

            
        

        

        
        
        

            

  
Safety & Side Effects





            

                
                

                    
已报告的副作用

                    
    
                        
                        
  • 
                            ⚠
                            GI side effects (diarrhea, constipation, flatulence, abdominal pain) — most common
                        
    • 
                        
                        
  • 
                            ⚠
                            May cause uterine contractions (contraindicated in pregnancy)
                        
    • 
                        
                        
  • 
                            ⚠
                            Headache
                        
    • 
                        
                        
  • 
                            ⚠
                            Skin rash (rare)
                        
    • 
                        
                    

                

                

                
                

                    
已知相互作用

                    
    
                        
                        
  • 
                            ●
                            Diabetes medications (berberine significantly lowers blood sugar; risk of hypoglycemia)
                        
    • 
                        
                        
  • 
                            ●
                            Cyclosporine (berberine inhibits CYP3A4, increasing cyclosporine levels)
                        
    • 
                        
                        
  • 
                            ●
                            Anticoagulants (may have additive blood-thinning effects)
                        
    • 
                        
                        
  • 
                            ●
                            Metformin (additive glucose-lowering effect; monitor closely)
                        
    • 
                        
                        
  • 
                            ●
                            Macrolide antibiotics (berberine inhibits CYP3A4)
                        
    • 
                        
                    

                

                

                
                

                    

                        可耐受最高摄入量： Generally well-tolerated up to 1,500 mg/day in divided doses
                    

                

                
            

            

                在开始服用任何补充剂之前，请务必咨询您的医疗保健提供者。
            

        

        

        
        
        

            

  
Frequently Asked Questions





            




    
    

        
            Does Berberine help with Small Intestinal Bacterial Overgrowth (SIBO)?
            
        
        

            Based on 2 studies with 180 participants, there is limited but promising evidence that Berberine may support Small Intestinal Bacterial Overgrowth (SIBO) management. Our evidence grade is C (Some Evidence).
        

    

    
    

        
            How much Berberine should I take for Small Intestinal Bacterial Overgrowth (SIBO)?
            
        
        

            Studies have used various dosages. A commonly studied range is 500-1,500 mg/day in divided doses. Always consult your healthcare provider before starting any supplement regimen.
        

    

    
    

        
            Are there side effects of Berberine?
            
        
        

            Reported side effects may include GI side effects (diarrhea, constipation, flatulence, abdominal pain) — most common, May cause uterine contractions (contraindicated in pregnancy), Headache, Skin rash (rare). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
        

    

    
    

        
            How strong is the evidence for Berberine and Small Intestinal Bacterial Overgrowth (SIBO)?
            
        
        

            We rate the evidence as Grade C (Some Evidence). This rating is based on 2 peer-reviewed studies with 180 total participants. The overall direction of effect is positive.
        

    

    




        

        

        
        
        

            

  
Related Evidence





            

                
                

                    
其他成分用于 Small Intestinal Bacterial Overgrowth (SIBO)

                    

                        
                        
                            Partially Hydrolyzed Guar Gum (PHGG)
                            C

                        
                        
                    

                

                

                
                

                    
Berberine 用于其他健康状况

                    

                        
                        
                            Acute Diarrhea
                            C

                        
                        
                        
                            Gut Dysbiosis
                            D

                        
                        
                    

                

                
            

        

        

    


    
    












    

        FDA 免责声明:
        这些声明未经美国食品药品监督管理局（FDA）评估。本网站上的产品和信息无意用于诊断、治疗、治愈或预防任何疾病。所展示的证据等级基于我们对已发表的同行评审研究的分析，不构成医疗建议。在开始任何补充剂方案之前，请务必咨询您的医疗保健提供者。